葵花SUNFLOWER品牌怎么样 申请店铺

我要投票 葵花SUNFLOWER在医疗保健行业中的票数:679 更新时间:2025-08-15
葵花SUNFLOWER是哪个国家的品牌?「葵花SUNFLOWER」是 葵花药业集团股份有限公司 旗下著名品牌。该品牌发源于黑龙江哈尔滨市,由创始人关玉秀在2005-09-07期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力葵花SUNFLOWER品牌出海!将品牌入驻外推网,定制葵花SUNFLOWER品牌推广信息,可以显著提高葵花SUNFLOWER产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

葵花SUNFLOWER怎么样

黑龙江葵花药业集团有限公司,黑龙江名牌,以胃康灵为代表的胃肠用药和小儿肺热咳喘口服液为代表的儿童用药著称


葵花药业集团是以中成药为主,以化学药、生物药、补益保健类产品为辅,集药品制造、营销、科研于一体的大型民营医药企业集团。现拥有五常葵花、伊春葵花、佳木斯葵花、佳木斯(鹿灵)葵花、唐山葵花、衡水葵花、冀州葵花、重庆葵花、隆中葵花、武当葵花、临江葵花、贵州葵花等12家药品生产企业,4家医药公司,1个药物研究院,1个药材种植基地,1个药品包材公司等23家子公司。2014年,在深圳证券交易所成功上市(股票代码:002737)。

在产品布局上,由改制初期的一个产品打天下,现发展为拥有15个剂型、1132个药品批准文号,其中,有29个品种、566个医保目录品种、274个基本药物品种,形成了儿科、妇科、消化系统、呼吸感冒、风湿骨伤病和心脑血管慢病6大特色产品集群,完成了从品种到品牌、再到品类的转化。

在科技研发上,葵花曾成功研发出以护肝片、胃康灵胶囊为代表的全国知名中药产品,为我国中药事业的发展做出了突出贡献。现在北京和哈尔滨分别设立了药物研究院,在各企业均设立了科研所,专注于中药、天然药物、化药的研究开发,通过“买、改、联、研”的研发战略,来不断提高企业创新发展能力。


Heilongjiang sunflower Pharmaceutical Group Co., Ltd., a famous brand in Heilongjiang Province, is famous for gastrointestinal medicine represented by Weikangling and children's lung heat cough and asthma oral liquid. Sunflower Pharmaceutical Group is a large-scale private pharmaceutical enterprise group mainly composed of proprietary Chinese medicine, supplemented by chemical medicine, biological medicine, tonic and health care products, integrating drug manufacturing, marketing and scientific research. Now it has 12 pharmaceutical manufacturers, 4 pharmaceutical companies, 1 Pharmaceutical Research Institute, 1 pharmaceutical planting base, 1 pharmaceutical packaging company and 23 subsidiaries, including Wuchang sunflower, Yichun sunflower, Jiamusi sunflower, Jiamusi (Luling) sunflower, Tangshan sunflower, Hengshui sunflower, Jizhou sunflower, Chongqing sunflower, Longzhong sunflower, Wudang sunflower, Linjiang sunflower and Guizhou sunflower. In 2014, it was successfully listed on Shenzhen Stock Exchange (Stock Code: 002737). In terms of product layout, it has developed from a product in the early stage of restructuring to a product with 15 dosage forms and 1132 drug approval numbers, including 29 varieties, 566 medical insurance catalog varieties and 274 basic drug varieties, forming 6 characteristic product clusters of Pediatrics, gynecology, digestive system, respiratory, rheumatism and osteopathy, and chronic cardiovascular and cerebrovascular diseases, completing the transformation from varieties to brands , and then to category transformation. In terms of scientific and technological research and development, sunflower has successfully developed national famous traditional Chinese medicine products represented by Hugan tablet and Weikangling capsule, which has made outstanding contributions to the development of traditional Chinese medicine in China. Now, Beijing and Harbin have set up drug research institutes respectively, and scientific research institutes have been set up in all enterprises, focusing on the research and development of traditional Chinese medicine, natural medicine and chemical medicine. Through the R & D strategy of "purchase, reform, joint research and development", the innovation and development ability of enterprises has been continuously improved.

本文链接: https://brand.waitui.com/49cab8429.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

南向资金净买额达300亿港元

36氪获悉,南向资金净买额达300亿港元,为今年4月9日以来首次

2小时前

礼来投资AI制药公司Superluminal

当地时间8月14日,礼来宣布与美国AI制药公司Superluminal签署价值13亿美元的交易,以加速AI药物研发,尤其是开发针对肥胖症及其他心脏代谢性疾病治疗的小分子药物。Superluminal是一家总部位于美国波士顿的AI制药初创型企业,该公司获得了包括英伟达在内的资本投资。(第一财经)

2小时前

菲律宾政府为三星10亿美元项目提供激励措施

菲律宾商务通消息,据《菲星报》8月14日报道,菲经济特区管理署(PEZA)称,计划在本季度内敲定激励方案,其中包括为三星电机菲律宾公司(SEMPHIL)计划投资的10亿美元项目提供的电力补贴,各方已就电价达成一致,将于本周将方案提交财政激励审查委员会(FIRB)审批,FIRB批准后,将提交总统办公室(OP),OP批准后,将流转至PEZA,预计三季度完成审批程序。(界面)

2小时前

工银资本等在四川成立兴眉工融基金

36氪获悉,爱企查App显示,近日,四川兴眉工融股权投资基金合伙企业(有限合伙)成立,执行事务合伙人为工银资本管理有限公司、四川兴川重点项目股权投资基金管理有限公司,出资额10亿元人民币,经营范围包括以私募基金从事股权投资、投资管理、资产管理等活动等。合伙人信息显示,该基金由眉山东坡国有资本投资运营集团有限公司、工银金融资产投资有限公司、四川兴川重点项目股权投资基金管理有限公司等共同出资。

2小时前

中国核建:截至2025年7月累计新签合同904.8亿元

36氪获悉,中国核建公告,截至2025年7月,公司累计新签合同904.80亿元,累计实现营业收入582.29亿元。

2小时前

本页详细列出关于葵花SUNFLOWER的品牌信息,含品牌所属公司介绍,葵花SUNFLOWER所处行业的品牌地位及优势。
咨询